NCT01768039

Vitamine D in Multiple Sclerosis

Randomised Double Blind Placebo-controlled Trial of Vitamine D Supplement in Multiple Sclerosis

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: Mazandaran University of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

Two hundred and forty patients with multiple sclerosis who met the study criteria will be enrolled in this randomized double blind placebo-controlled clinical trial. They will randomly assigned to placebo or vitamin D treatment group. The total time of study is 52 weeks and the vitamin D group will be treated by weekly 50000 International unit(IU) vitamin D, while the other group will receive weekly placebo. The annual relapse rate and EDSS will be compared at baseline, month 6 and 12.

Conditions

• Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	Vitamin D
DRUG	Placebo

Timeline

• Start date: 2013-03-01
• Primary completion: 2014-08-01
• Completion: 2014-10-01
• First posted: 2013-01-15
• Last updated: 2013-01-15

Locations

1 site across 1 country: Iran